KNOWLEDGE BANK

Interviews

Ensuring Ethics in AI-Driven Drug Safety

Senior Director of Pharmacovigilance and Risk Management at Curis Inc.
Ashish Jain is Senior Director of Pharmacovigilance and Risk Management at Curis Inc with over years of experience in drug safety He is also leading the Innovation Working Group at the North American Society of Pharmacovigilance NASoP his expertise in combining technological innovation with patient safety makes him uniquely qualified to address the ethical challenges of AI implementation in pharm...

Articles

Nanotechnology based Drug Delivery for Infectious Diseases

Infectious diseases continue to pose a serious threat to global health particularly in the face of rising antimicrobial resistance AMR emerging viral outbreaks COVID and neglected tropical diseases with an estimated million fatalities linked to bacterial AMR in The WHO research agenda for antimicrobial resistance AMR in human health has selected research priorities to be addressed by the year

Research Insights

Investigator-initiated Clinical Trials Conducted By The Portuguese Clinical Research Infrastructure Network (PtCRIN)

Abstract Interventional clinical studies can provide the highest levels of evidence and generate significant results on specific investigational medicinal products or medical devices In order to have powerful studies attain unquestionable results and make significant discoveries the number of patients enrolled must be high Therefore multinational randomis

Case Studies

Effects Of Particle Size On The Triboelectrification Phenomenon In Pharmaceutical Excipients: An Experimental Case Study

Abstract Particle sizes play a major role to mediate charge transfer both between identical and different material surfaces The study probes in to the probable mechanism that actuates opposite polarities between two different size fractions of the same material by analyzing the charge transfer patterns of two different sizes of MCC Quantum scale calculations

Techno Trends

ENHERTU® Breakthrough Therapy Discovered for Low Metastatic Breast Cancer

Daiichi Sankyo and AstraZenecas jointly discovered ENHERTU famtrastuzumab deruxtecannxki breakthrough therapy for the treatment of patients with HER low metastatic breast cancer ENHERTU is an engineered HER directed antibody drug conjugate ADC ENHERTU has been developed for adult patients with unresectable

White Papers

Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches

In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS

TOP ARTICLES

1

Tiny Vesicles, Big Impact

Disha Marwaha

Dr. Disha Marwaha received her PhD in biological sciences from CSIR-Central Drug Research Institute (CSIR-CDRI), India in 2024. She is currently an Assistant Professor at the GLA University, Mathura. She has more than 20 publications in international peer-reviewed Journals. She is an expert in formulation and development, nanomedicine and pharmacokinetics focusing on innovative therapeutic and targeted drug delivery systems.

Neha Singh

Dr. Neha Singh received her Ph.D. in Biological Sciences from the CSIR-Central Drug Research Institute (CSIR-CDRI), India, in 2025. She is currently an Assistant Professor at the Lloyd School of Pharmacy, Greater Noida. Dr. Singh has contributed extensively to the field of pharmaceutical sciences, with many publications, patents, and book chapters in internationally recognised peer-reviewed journals. Her primary research interests include formulation development, nanomedicine and pharmacokinetics, with a focus on innovative therapeutic strategies and targeted drug delivery systems. Dr. Singh’s work reflects her commitment to advancing precision medicine and developing next-generation solutions for healthcare.

2

Viksit Bharat@ 2047 envisioned the Indian Pharma Industry

Md. Faiyazuddin

Professor Md. Faiyazuddin, a distinguished academician with extensive experience working across the government, public and private sectors, sought to leverage his sixteen-year background in pharmacy education, product development, research consultation, and social pharmacy outreach activities in academia and industry. He is a Senior Professor and former Dean, R&D, Al-Karim University, who is lecturing on health and drug delivery research and holds visiting positions at prestigious universities in India and abroad. He has successfully completed research grants from various R&D agencies, such as SERB-DST and foreign agencies (DSR-UoH, DST, UiTM, Malaysia, Sick’s Children Hospital, Canada) worth Rs. 1.12 Million INR. With more than 120 research, conference, and review manuscripts, dozens of books and chapters, 15 accolades and awards, and various IPR have contributed greatly to the pharm fraternity of India. In addition to his daily job, Dr. Faiyazuddin has a keen interest in connecting researchers worldwide for practicing safe drugs under the flagship of the International Pharmaceutical Forum (a community of more than 250 pharma stalwarts across the globe).

 

Yogesh Subhash Chaudhari

Yogesh Subhash Chaudhari, a passionate educator at Dr L H Hiranandani College of Pharmacy, has contributed significantly to this field through research and review of papers in prestigious journals. His insights on AI for Pharmacist Newsletters on Linkedin are as follows.

 

3

Beyond The Needle

Dr. Sanjesh Kumar

Dr. Sanjesh Kumar is an Assistant Professor at Chandigarh University Uttar Pradesh with a Ph.D. in Pharmacology. An award-winning academician specialized in neurodegenerative disorders and advanced drug delivery, he has authored over 45 high-impact publications and holds multiple patents, seamlessly bridging the gap between clinical research and classroom education.

Dr. Mansi Singh

Dr. Mansi Singh is an academician and researcher serving as Guest Faculty at Babasaheb Bhimrao Ambedkar University, holding a Ph.D. in Pharmacology. A NET and GPAT qualified expert, she is specialized in neuropharmacology and toxicology. She has over six years of teaching experience and has authored more than 40 publications, copyright and multiple patents.

4

Artificial Intelligence - A current and future tool to learn chemical sciences

Ruchi Bharti

Ruchi Bharti received her M.Sc. from Patna University, in organic chemistry. PhD from National Institute of Technology Patna (NIT Patna), in 2012. There she worked on the development of new organocatalysts and their utilization in the synthesis of diverse heterocyclic compounds via multimulticomponent reactions. In 2017, she enrolled as assistant professor at R. P Sharma Institute of Technology, Since 2018, she joined Department of Chemistry, University Institute of Sciences, Chandigarh University, Punjab as Assistant Professor. Her recent research work is focused on the functionalisation of diverse heterocycles, multicomponent reactions, organocatalysis and their related biological and medicinal applications.

 

5

Therapeutic Peptides

Rienzi Mosqueda

Rienzi Mosqueda is a dedicated writer specialising in life science, health, and pharma content. With a passion for clear, engaging writing, Rienzi provides fresh perspectives on each topic. His ability to simplify complex ideas makes the articles valuable for readers of all backgrounds. As an emerging voice, Rienzi Mosqueda is committed to sharing knowledge and sparking discussions through their impactful writing.

 

press releasesRead more...

Enhertu approved in the EU as adjuvant treatment for patients with residual disease after neoadjuvant treatment for HER2-positive early breast cancer

AstraZeneca and Daiichi Sankyos Enhertu trastuzumab deruxtecan has been approved in the European Union EU as a monotherapy for the adjuvant treatment of adult patients with resected HERpositive breast cancer who have residual invasive disease after neoadjuvant taxanebased and HERtargeted treatment

Teva Acquires Worldwide Rights to BXCL501, Further Expanding Innovative Neuroscience Pipeline

Teva Pharmaceuticals International GmbH a subsidiary of Teva Pharmaceutical Industries Ltd today announced that it has completed the acquisition of assets from BioXcel Therapeutics Inc including worldwide rights to BXCL BXCL is an investigational dexmedetomidine

Ferring Pharmaceuticals and Gameto sign agreement for proposed acquisition

Ferring Pharmaceuticals and Gameto today announced that they have signed an agreement for a global transaction under which Ferring would acquire Gameto Completion remains subject to customary and other closing conditions Until closing the companies will continue to operate independently

Innovent Announces NMPA Acceptance of a New Indication Application of Sintilimab for the Treatment of Advanced Melanoma

Innovent Biologics Inc a worldclass biopharmaceutical company that develops manufactures and commercializes high quality medicines for the treatment of cancer metabolic autoimmune and other major diseases today announced that a New Indication Application for sintilimab in combination with Nolgileuce...

Georgiamune and Menarini Group Enter Exclusive Global License and Collaboration Agreement for GIM-621, a First-in-Class Oral Immuno-Oncology Agent

The Menarini Group Menarini a leading international pharmaceutical and diagnostics company and Stemline Therapeutics Inc Stemline a whollyowned subsidiary of the Menarini Group focused on bringing transformational oncology treatments to cancer patients along with Georgiamune Inc a clinicalstage biot...

Aptar Pharma Acquires Pulmotree, Expanding Growth Opportunities in Next-Generation Pulmonary Drug

Aptar Pharma a global leader in drug delivery dosing protection technologies and services today announced the strategic acquisition of PULMOTREE a Munich Germanybased life science company specializing in pulmonary drug delivery systems for targeted delivery to the lungs The acquisition is expected t...

EventsRead more...

26 - 28

Oct 2026

ACHEMA Middle East 2026

RICEC, Riyadh, KSA, Saudi Arab...

26 - 28

Oct 2026

World Orphan Drug Congress

RAI, Amsterdam, Netherlands

27 - 28

Oct 2026

PM& AC 2026

Novotel Hyderabad Convention C...

28 - 30

Oct 2026

02 - 04

Nov 2026

Pharma Forum EMEA 2026

Dom Pedro Lisboa Hotel, Lisbon...

02 - 04

Nov 2026

Cancer R&D 2026

Houston, TX, USA

03 - 05

Nov 2026

10th Dermatology Drug Development

Boston, Massachusetts at The C...

03 - 04

Nov 2026

PDA Aseptic Processing of Biopharma Conference

Sheraton Grand Incheon Hotel,...

LATEST NEWSRead more...

Astellas Enters into Agreement with Audax for Immuno-Oncology Candidate DAX-044

Astellas Pharma and Audax Biosciences have entered into an exclusive option and licence agreement for DAX an investigational antibodycytokine fusion being developed for cancer immunotherapy DAX is designed to deliver interleukin IL an immuneactivating protein more selectively to the tumour microenvi...

Sumitomo Pharma’s Enzomenib Receives Breakthrough Therapy Designation for Relapsed or Refractory KMT2A-Rearranged Acute Leukaemia

Sumitomo Pharma America has announced that the US Food and Drug Administration FDA has granted Breakthrough Therapy designation to enzomenib DSP for treating patients with relapsed or refractory acute leukaemia carrying a KMTA gene rearrangement

Pfizer’s TALZENNA Plus XTANDI Approved for Earlier Treatment of Metastatic Prostate Cancer

Pfizer has received approval from the US Food and Drug Administration FDA to expand the use of TALZENNA talazoparib in combination with XTANDI enzalutamide for men with metastatic prostate cancer that is sensitive to hormone treatment and has specific homologous recombination repair HRR gene mutatio...

Okomera Signs Agreement with Servier for Cancer Research Technology

Okomera has signed a commercial agreement with Servier to support the development of new cancer treatments using its tumour miniaturisation technology More than of oncology drug candidates fail to reach the market making it important to identify promising treatments at an early stage Okomeras platf...

AstraZeneca and Oracle Launch Global AI Collaboration to Optimise Clinical Trials

AstraZeneca and Oracle Health and Life Sciences have launched a global collaboration to use artificial intelligence AI realworld data and cloud technology to improve clinical trial efficiency and patient outcomes The collaboration will combine AstraZenecas expertise in drug development clinical rese...

UCB Receives Approval for ZILBRYSQ Autoinjector for Adults with Generalised Myasthenia Gravis

UCB has received approval from the US Food and Drug Administration FDA for a new autoinjector option for ZILBRYSQ zilucoplan a treatment for adults with generalised myasthenia gravis gMG who test positive for antiacetylcholine receptor AChR antibodies